Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

  1. Mateos, M.V.
  2. Weisel, K.
  3. Terpos, E.
  4. Delimpasi, S.
  5. Kastritis, E.
  6. Zamagni, E.
  7. Delforge, M.
  8. Ocio, E.
  9. Katodritou, E.
  10. Gay, F.
  11. Larocca, A.
  12. Leleu, X.
  13. Otero, P.R.
  14. Schjesvold, F.
  15. Cavo, M.
  16. Dimopoulos, M.A.
Revue:
Haematologica

ISSN: 1592-8721,  0390-6078

Année de publication: 2024

Volumen: 109

Número: 7

Pages: 2337-2340

Type: Lettre

DOI: 10.3324/HAEMATOL.2023.284694 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus